DENNIS H BIRENBAUM
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology DALLAS, TX NPI 1538119045
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX NOVARTIS PHARMACEUTICALS CORPORATION All categories
This page merges CMS profile IDs: 11429720, 115263 (associated profiles published by CMS for the same provider; see the provenance section below).
General Payments — all program years on this page
$8,204.98
- Category: General Payments
- Program years: PY2018–2022
- Record count: 415
- As of (CMS publication): 2026-01-23
Latest program year (PY2022): $1,192.51 across 52 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2022) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $925.90 | 49 |
| Long term medical supply or device loan | $166.66 | 2 |
| Education | $99.95 | 1 |
By paying entity
Latest program year (PY2022) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $310.75 | 11 |
| Amgen Inc. | $126.85 | 3 |
| PFIZER INC. | $77.15 | 5 |
| EMD Serono, Inc. | $74.80 | 4 |
| Celgene Corporation | $68.24 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $63.16 | 3 |
| Acrotech Biopharma Inc. | $60.34 | 1 |
| TAIHO ONCOLOGY, INC. | $53.67 | 3 |
| E.R. Squibb & Sons, L.L.C. | $53.27 | 4 |
| EISAI INC. | $48.45 | 2 |
| Foundation Medicine, Inc. | $27.40 | 1 |
| Global Blood Therapeutics, Inc. | $24.63 | 1 |
| Coherus Biosciences Inc. | $22.67 | 1 |
| Gilead Sciences, Inc. | $21.52 | 1 |
| Merck Sharp & Dohme Corporation | $20.73 | 1 |
| Janssen Biotech, Inc. | $19.67 | 1 |
| Genentech USA, Inc. | $19.44 | 1 |
| Kite Pharma, Inc. | $18.88 | 1 |
| Janssen Pharmaceuticals, Inc | $18.61 | 1 |
| Karyopharm Therapeutics Inc. | $17.88 | 1 |
| GlaxoSmithKline, LLC. | $17.01 | 1 |
| Incyte Corporation | $15.44 | 1 |
| TACTILE SYSTEMS TECHNOLOGY INC | $11.95 | 1 |
By program year
Records — PY2022 (52)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
- Merged CMS profile IDs: 11429720, 115263
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.